The CART_Andalucía project has officially taken its first steps. This pioneering initiative focuses on developing advanced and innovative therapies against cancer, with €4.28 million in funding from the European Regional Development Fund (ERDF). Its goal: to design a new generation of CAR-T therapies that are more effective, safer, and accessible for patients with hematological cancers such as lymphomas and leukemias.

After a highly competitive tendering process, contracts for Phase 1 of the project have been awarded to two temporary business consortiums (UTEs) with strong scientific and technological backgrounds in biotechnology and immunotherapy. Among them is UTE BBZS_CAR-T, formed by BIAT GROUP, Biogipuzkoa, ZIP Solutions S.L., and Science & Innovation Link Office (SILO).

At ZIP Solutions (part of the BIAT Group, ticker BST), we are contributing Click-CAR, our proprietary technology based on split inteins that enables the creation of modular CAR therapies that are both safer and more effective. Our commitment to innovation in advanced therapies reinforces the project’s mission: to bring next-generation immunotherapy closer to the public healthcare system.

The Progreso y Salud Foundation, through the OTCPI Salud, manages this ambitious program within the framework of the Public Procurement of Innovation Strategy of the Andalusian Public Health System (SSPA), with the support of the Andalusian Network for the Design and Translation of Advanced Therapies (RADyTTA).

With an initial duration of three months, this first stage will lay the groundwork for the next phases: preclinical development and validation of the new CAR-T therapy.

🔬 CART_Andalucía strengthens the region’s leadership in cellular immunotherapy and marks a milestone in public–private collaboration for the development of next-generation cancer treatments.

👉 Learn more about the project at the following link: https://www.car-tproject.com